Boehringer Ingelheim opens its new office in Kuwait

Boehringer Ingelheim, one of the world's leading pharmaceutical business, revealed today that it has actually recently opened its brand-new office in the State of Kuwait. The opening event was kept in YIACO Medical Company's (YIACO) headquarters, in Salmiya, and where senior agents from both companies were present.

YIACO's management team included Dr. Bader Altraiji, Chief Executive Officer; Dr. Mohamed Barham, Chief Operational Officer; Dr. Fawaz Al Omi, Chief Communications Officer and Dr. Abdulla Al Bader, Pharmaceutical and Healthcare Manager. Representing Boehringer Ingelheim were Mazen Bachir, Country Manager-- Gulf and Iran and the company's wider team in Kuwait.

During the opening event, Mazen Bachir stated, "Kuwait is a important market for Boehringer Ingelheim's operations in the region, and we are proud to team up with our agent, YIACO, to provide patient focused solutions. Our dedication to excellence and extensive understanding of patient needs in Kuwait makes us positive to deliver value throughout a variety of restorative locations including diabetes, breathing, cardiovascular diseases as well as lung cancer."
" Our goal is to continue growing our presence in Kuwait to reach a team of 25-30 employees while increasing our overall company in the coming couple of years," included Bachir.

Dr. Bader Al Traji, Chief Executive Officer of YIACO also stated, "The ongoing development of Kuwait's population and increase in conditions such as diabetes and obesity has actually triggered more needs for a more powerful healthcare offering. We are proud to partner with Boehringer Ingelheim to broaden their presence throughout the country with an underlying objective of additional enhancing community wellbeing."

Boehringer Ingelheim is committed to research into patient populations to improve the overall understanding of their conditions and patient experiences.